Recorded webinar ∙ By Philips Healthcare ∙ Jun 28, 2023 ∙ 3 min read
“Finland has pioneered digital pathology for over 15 years but projects leading to full scale adaption in clinical diagnostics have been lacking for multiple reasons (technical prerequisites, financial considerations etc.). Now it seems that these barriers have been overcome and currently there are many centers planning to go digital. This presentation will reveal our initial experiences of going ~ 100% digital in a multicenter environment.”
Dr. Teemu Tolonen, Project manager, Digital Pathology Head of Department, Fimlab Laboratories, Finland
Dr. Teemu Tolonen, Project manager, Digital Pathology Head of Department, Fimlab Laboratories, Finland
Teemu Tolonen graduated from the University of Tampere with a Doctorate of Medicine and Doctorate of Philosophy with a focus in cancer genetics. He became an adjunct professor of pathology in 2019. In 2010 he began his residency at Fimlab Laboratories, one of the leading laboratory companies in Finland, providing laboratory services, education, and research in Pirkanmaa, Central Finland, Kanta-Häme, Ostrobothnia and Paijät-Hame regions. In 2017 Dr. Tolonen became the Head of the department of pathology at Fimlab Laboratories. Over the course of his career, Dr. Tolonen has served key roles for the Finnish Division of the International Academy of Pathology (IAP), as a board member (2014-2015) and President (2016-2017/2018-2019). Dr. Tolonen has 62 publications that include scientific publications on genitourinary lab cancers and digital image analysis.
Results are specific to the institution where they were obtained and may not reflect the results achievable at other institutions.
You are about to visit a Philips global content page
ContinueThe information on this site is not intended for consumers. The information is directed exclusively to health professionals, health practitioners, persons who are purchasing officers in hospitals, and persons who are engaged in the business of wholesaling therapeutic goods (as per s42AA of the Therapeutic Goods Act 1989 (Cth), and s6 of the Therapeutic Goods (Therapeutic Goods Advertising Code) Instrument 2021).
By clicking “Continue” you are indicating that you are one of the intended audiences. Click cancel to be redirected to the Philips website.